Check-Cap Ltd. (CHEK)
$3.5
-0.29 (-7.65%)
Rating:
Recommendation:
Buy
| Symbol | CHEK |
|---|---|
| Price | $3.5 |
| Beta | 0.777 |
| Volume Avg. | 0.10M |
| Market Cap | 20.474M |
| Shares () | - |
| 52 Week Range | 1.22-6.54 |
| 1y Target Est | - |
| DCF Unlevered | CHEK DCF -> | |
|---|---|---|
| DCF Levered | CHEK LDCF -> | |
| ROE | -50.89% | Strong Sell |
| ROA | -57.89% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 0.27% | Neutral |
| P/E | -1.10 | Sell |
| P/B | 0.68 | Buy |
Latest CHEK news
About
Download (Excel)Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.